Cost-effectiveness analysis in severe mental illness: Outcome measures selection

Journal of Mental Health Policy and Economics

Volumn 10, Issue 2, 2007, Pages 101-108

  Stant, A Dennis ^a   Buskens, Erik ^a   Jenner, Jack A ^a   Wiersma, Durk ^a   Ten Vergert, Elisabeth M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; ECONOMIC EVALUATION; HEALTH CARE POLICY; HUMAN; MEDICAL DECISION MAKING; MENTAL DISEASE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOTHERAPY; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; HALLUCINATIONS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOTHERAPY; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SCHIZOPHRENIA;

EID: 34447314444     PISSN: 10914358     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Kanavos P, Trueman P, Bosilevac A. Can economic evaluation guidelines improve efficiency in resource allocation? The cases of Portugal, the Netherlands, Finland, and the United Kingdom. Int J Technol Assess Healthcare 2000; 16: 1179-1192.
2. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296: 716-721.
3. Schwappach DL. Resource allocation, social values and the QALY: a review of the debate and empirical evidence. Health Expect 2002; 5: 210-222.
4. Buskens E. Value of cost-utility analysis; evidence-based policy making [article in Dutch]. Ned Tijdschr Geneeskd 2004; 148: 1074-1076.
5. Chisholm D, Healey A, Knapp M. QALYs and mental healthcare. Soc Psychiatry Psychiatr Epidemiol 1997; 32: 68-75.
6. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the economic evaluation of Healthcare Programmes. Oxford: Oxford University Press, 1997.
7. Evers SMAA, Van Wijk AS, Ament AJHA. Economic evaluation of mental healthcare interventions. A review. Health Econ 1997; 6: 161-177.
8. McCrone P, Leese M, Thornicroft G, Schene A, Knudsen HC, Vazquez-Barquero JL, Tansella M, Becket T. A comparison of needs of patients with schizophrenia in five European countries: the EPSILON study. Acta Psychiatr Scand 2001; 103: 370-379.
9. Ravindran AV, Matheson K, Griffiths J, Merali Z, Anisman H. Stress, coping, uplifts, and quality of life in subtypes of depression: a conceptual frame and emerging data. J Affect Disord 2002; 71: 121 - 130.
10. Compton SN, Swanson JW, Wagner HR, Swartz MS, Burns BJ, Elbogen EB. Involuntary outpatient commitment and homelessness in persons with severe mental illness. Ment Health Serv Res 2003; 5: 27-38.
11. McGurk SR, Mueser KT. Cognitive functioning and employment in severe mental illness. J Nerv Ment Dis 2003; 191: 789-798.
12. Hansson L. Outcome assessment in psychiatric service evaluation. Soc Psychiatry Psychiatr Epidemiol 2001; 36: 244-248.
13. Cooper LA, Brown C, Vu HT, Palenchar DR, Gonzales JJ, Ford DE, Powe NR. Primary care patients' opinions regarding the importance of various aspects of care for depression. Gen Hosp Psychiatry 2000; 22: 163-173.
14. Wiersma D, Van Busschbach J. Are needs and satisfaction of care associated with quality of life? An epidemiological survey among the severely mentally ill in the Netherlands. Eur Arch Psychiatry Clin Neurosci 2001; 251: 239-246.
15. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. Oxford: Oxford University Press, 1996.
16. Stant AD, TenVergert EM, Groen H, Jenner JA, Nienhuis FJ, Van de Willige G, Wiersma D. Cost-effectiveness of the HIT programme in patients with schizophrenia and persistent auditory hallucinations. Acta Psychiatr Scand 2003; 107: 361-368.
17. Jenner JA. An integrative treatment for patients with persistent auditory hallucinations. Psychiatr Serv 2002; 53: 897-898.
18. Wiersma D, Jenner JA, Nienhuis FJ, Van de Willige G. Hallucination focused integrative treatment improves quality of life in schizophrenia patients. Acta Psychiatr Scand 2004; 109: 194-201.
19. Van de Willige G, Wiersma D, Jenner JA, Nienhuis FJ. Changes in quality of life in chronic psychiatric patients: a comparison between EuroQol (EQ-5D) and WHOQoL. Qual Life Res 2005; 14: 441-451.
20. Jenner JA, Nienhuis FJ, Wiersma D, Van de Willige G. Hallucination focused integrative treatment: a randomized controlled trial. Schizophr Bull 2004; 30: 133-145.
21. Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl 1989; 7: 59-67.
22. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Manual for cost studies, methods and standard prices for economic evaluation in health care [In Dutch: Handleiding voor kostenonderzoek, methoden en richtlijnprijzen voor economische evaluaties in de gezondheidszorg]. Amstelveen: Health Care Insurance Council, 2000.
23. Wiersma D, De Jong A, Kraaijkamp HJM, Ormel J. GSDS-II: the Groningen Social Disabilities Schedule, second version. Groningen: Rijksuniversiteit Groningen, 1990.
24. Haddock G, McCarron J, Tarrier N, Faragher EB. Scales to measure dimensions of hallucinations and delusions: The psychotic symptom rating scales (PSYRATS). Psychol Med 1999; 29: 879-889.
25. EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
26. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-1108.
27. WHOQoL Group. Development of the World Health Organisation WHOQoL-BREF quality of life assessment. Psychol Med 1998; 28: 551-558.
28. Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making 1990; 10: 212-214.
29. Briggs AH, O'Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 2002; 23: 377-401.
30. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman & Hall, 1993.
31. Van Hout BA, AI MJ, Gordon GS, Rutten FF. Costs, effects and C/E ratios alongside a clinical trial. Health Econ 1994; 3: 309-319.
32. Fenwick E, O'Brien BJ, Briggs AH. Cost-effectiveness acceptability curves - facts, fallacies and frequently asked questions. Health Econ 2004; 13: 405-415.
33. Mauskopf JA, Paul JE, Grant DM, Stergachis A. The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics 1998; 13: 277-288.
34. Hoffmann C, Stoykova BA, Nixon J, Glanville JM, Misso K, Drummond MF. Do health-care decision makers find economic evaluations useful? The findings of focus group research in UK health authorities. Value Health 2002; 5: 71-78.
35. Lewis SW, Davies L, Jones PB, Barnes TRE, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess 2006; 10: 1-165.
36. Skevington SM, Lotfy M, O'Connell KA. The World Health Organization's WHOQoL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQoL Group. Qual Life Res 2004; 13: 299-310.